Hamburg-based biotech company Topas Therapeutics has closed a €22m series-B round co-led by new investors Vesalius BioCapital III and BioMedPartners.
H2 Equity reinvests with minority share; sale saw interest from Partners, HIG, CapVest
With a EUR 300m hard cap, the fund could complete its first investment by H1 2023
Sale of parent company of specialist outdoor brands Rab and Lowe Alpine is the firm’s third exit this year
Energy sector investor prepares to raise EUR 350m for Article 9 fund targeting renewable, clean tech businesses